Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 + HLX87 in first-line HER2-positive recurrent/metastatic breast cancer
CTR20254885Phase 3Active
- Sponsor
- HyBioPharma
- Start
- Feb 2026
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hlx22, gq1005 in breast cancer, sponsored by HyBioPharma. Started Feb 2026; status: active.
02
Drugs
hlx22gq1005
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20254885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254885.